全文获取类型
收费全文 | 159733篇 |
免费 | 32946篇 |
国内免费 | 2479篇 |
专业分类
耳鼻咽喉 | 5223篇 |
儿科学 | 5617篇 |
妇产科学 | 2525篇 |
基础医学 | 4364篇 |
口腔科学 | 1639篇 |
临床医学 | 27108篇 |
内科学 | 50099篇 |
皮肤病学 | 7872篇 |
神经病学 | 15474篇 |
特种医学 | 7034篇 |
外科学 | 42951篇 |
综合类 | 281篇 |
现状与发展 | 72篇 |
一般理论 | 2篇 |
预防医学 | 7137篇 |
眼科学 | 3484篇 |
药学 | 1439篇 |
中国医学 | 29篇 |
肿瘤学 | 12808篇 |
出版年
2024年 | 686篇 |
2023年 | 4828篇 |
2022年 | 1288篇 |
2021年 | 3275篇 |
2020年 | 6155篇 |
2019年 | 2298篇 |
2018年 | 7564篇 |
2017年 | 7517篇 |
2016年 | 8663篇 |
2015年 | 8645篇 |
2014年 | 15816篇 |
2013年 | 16003篇 |
2012年 | 5987篇 |
2011年 | 6099篇 |
2010年 | 10755篇 |
2009年 | 14586篇 |
2008年 | 6447篇 |
2007年 | 4681篇 |
2006年 | 7163篇 |
2005年 | 4453篇 |
2004年 | 3668篇 |
2003年 | 2616篇 |
2002年 | 2777篇 |
2001年 | 3888篇 |
2000年 | 3080篇 |
1999年 | 3327篇 |
1998年 | 3842篇 |
1997年 | 3609篇 |
1996年 | 3536篇 |
1995年 | 3358篇 |
1994年 | 2057篇 |
1993年 | 1666篇 |
1992年 | 1465篇 |
1991年 | 1477篇 |
1990年 | 1140篇 |
1989年 | 1230篇 |
1988年 | 1063篇 |
1987年 | 897篇 |
1986年 | 924篇 |
1985年 | 746篇 |
1984年 | 593篇 |
1983年 | 549篇 |
1982年 | 545篇 |
1981年 | 437篇 |
1980年 | 396篇 |
1979年 | 322篇 |
1978年 | 345篇 |
1977年 | 409篇 |
1975年 | 284篇 |
1972年 | 309篇 |
排序方式: 共有10000条查询结果,搜索用时 15 毫秒
41.
42.
Sentinel lymph node biopsy for 102 patients with primary cutaneous melanoma at a single Japanese institute
下载免费PDF全文
![点击此处可从《The Journal of dermatology》网站下载免费的PDF全文](/ch/ext_images/free.gif)
Masaki Otsuka Osamu Yamasaki Tatsuya Kaji Keiji Iwatsuki Kenji Asagoe 《The Journal of dermatology》2015,42(10):954-961
Sentinel lymph node biopsy (SLNB) is a widely accepted standard procedure for patients with clinically localized melanoma. Melanoma prevalence and Clark's subtype differ between Asians and Caucasians. Here, we evaluated our experience on SLNB for cutaneous melanoma in a Japanese population. SLNB was performed for patients with melanoma between July 2000 and June 2014. We retrospectively analyzed 102 patients regarding association of clinicopathological features with sentinel lymph node (SLN) status, melanoma‐specific survival (MSS) and disease‐free survival (DFS). A positive SLN was significantly associated with primary Breslow thickness. Compared with 43 patients with negative SLN, 59 patients with positive SLN had significantly shorter MSS (5‐year survival rate, 94.3% vs 63.2%; P = 0.0002) and DFS (5‐year survival rate, 92.7% vs 63.4%; P = 0.0004). According to our subgroup analyses, nine patients with positive non‐SLN had significantly shorter MSS compared with 32 patients with negative non‐SLN (5‐year survival rate, 32.4% vs 68.5%; P = 0.0273). The survival of 51 Japanese patients with acral lentiginous melanoma (ALM) was not inferior to the survival of patients with other Clark's subtype. Breslow thickness is an important factor for both MSS and DFS, and the status of SLN is the most predictive prognostic factor in Japanese patients with clinically localized melanomas, as in case of Caucasians. Features of ALM may be different between Asians and Caucasians. 相似文献
43.
44.
Breast Elastography: How to Perform and Integrate Into a “Best-Practice” Patient Treatment Algorithm
Breast elastography has been available for more than 15 years but is not widely incorporated into clinical practice. Many publications report extremely high accuracy for various breast elastographic techniques. However, results in the literature are extremely variable. This variability is most likely due to variations in technique, a relatively steep learning curve, and variability in methods between vendors. This article describes our protocol for performing breast elastography using both strain elastography and shear wave elastography, which produces high sensitivity and specificity. Additionally, we will describe the most commonly known false-positive and false-negative lesions as well as how to detect them. 相似文献
45.
The term “oligometastatic prostate cancer” refers to a heterogeneous group of disease states currently defined solely on the basis of clinical features. Oligorecurrent disease, de novo oligometastases, and oligoprogressive disease likely have unique biologic underpinnings and natural histories. Evidence suggesting the existence of a subset of patients who harbor prostate cancer with limited metastatic potential currently includes disparate and overwhelmingly retrospective reports. Nevertheless, emerging prospective data have corroborated the “better-than-expected,” retrospectively observed outcomes, particularly in the setting of oligorecurrent prostate cancer. Improved functional imaging with prostate-specific membrane antigen-targeted strategies may enhance the identification of patients with oligometastatic prostate cancer in the short term. In the long term, refinement of the oligometastatic case definition likely will require biologic risk-stratification schemes. To determine optimal treatment strategies and identify patients most likely to benefit from metastasis-directed therapy, future efforts should focus on conducting high-quality, prospective trials with much-needed molecular correlative studies. 相似文献
46.
47.
48.
49.
50.
Marie V. Plaisime PhD MPH Marie Jipguep-Akhtar PhD Joseph J. Locascio PhD Harolyn M. E. Belcher MD MHS Rachel R. Hardeman PhD MPH Katherine Picho-Kiroga PhD Sylvia P. Perry PhD Sean M. Phelan PhD MPH Michelle van Ryn PhD LMFT MPH John F. Dovidio PhD 《Health services research》2023,58(Z2):229-237